News | Embolic Protection Devices | October 31, 2017

Distal Filter Embolic Protection Decreases No-reflow Phenomenon in ACS Patients With Attenuated Plaque

Primary endpoint occurred in more than 25 percent of DP patients versus more than 40 percent of patients randomized to conventional treatment

The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the incidence of no-reflow phenomenon after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients with attenuated plaque ≥5mm based upon intravascular imaging. It also examined its long-term effects.

Researchers enrolled 200 ACS patients who had a native coronary artery lesion and attenuated plaque with a longitudinal length of ≥5mm by pre-PCI IVUS. They were randomized to distal filter protection (DP) or conventional treatment (CT).

The primary endpoint of no-reflow phenomenon occurred in 26.5 percent in the DP group (N=98) and 41.7 percent in the CT group (N=96, P=0.0261) and the corrected TIMI frame count after revascularization was significantly lower in the DP group (23 vs. 30.5, P=0.0003). In addition, the incidence of in hospital adverse cardiac events was significantly lower in the DP group than in the CT group (0 percent vs. 5.2 percent, P=0.028).

“The selective use of embolic protection devices for patients at high risk for distal embolization is of great interest among interventional cardiologists,” said Kiyoshi Hibi, M.D., associate professor at Yokohama City University Medical Center in Yokohama, Japan. “VAMPIRE 3 shows that the use of distal embolic protection using a filter device decreased the incidence of no-reflow phenomenon with fewer serious adverse cardiac events after revascularization.”

The VAMPIRE 3 study was funded by Boston Scientific Corp., Nipro and Japan Lifeline. Hibi reported no disclosures.

For more information: www.tctconference.com

Related TCT Content

TCT Announces 2017 Late-breaking Clinical Trial Presentations

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major